vTv Therapeutics Inc VTVT
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2015-07-30 |
| Shares Out. | 3,940,000 |
| Website | vtvtherapeutics.com/ ↗ |
| Phone | 13026365400 |
| Employees | 26 |
| Revenue | $36.8M |
| Gross Profit | $36.8M |
| Net Income | $24.1M |
| Total Assets | $98.8M |
| Total Liabilities | $8.9M |
| Equity | $90.0M |
About vTv Therapeutics Inc
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
vTv Therapeutics Inc is a publicly traded company under the ticker symbol VTVT on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-07-01)